Newbury has signed a new licence and supply agreement with one of its existing partners to register and launch Guanfacine in Sweden. Guanfacine, 1, 2, 3 and 4 mg prolonged release tablets, is a selective alpha2A-adrenergic receptor agonist used in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.
“With the addition of Guanfacine, we are excited to strengthen our collaboration with one of our existing partners and further build out our fast-growing neuroscience portfolio. This agreement reinforces our ambition to be the partner of choice for international manufacturers entering the Nordic market, and to bring important new treatment options to patients in Sweden,” says Mr Karl Karlsson CEO of Newbury
Regulatory filing is expected in the near future, with launch of Guanfacine in Sweden planned upon regulatory approval. The total annual value of the relevant market in Sweden is estimated at 17 MEUR according to DLMI Nordic Pharma Insights.